Trademark: 97229628
Word
DIAMOND THERAPEUTICS
Status
Pending
Status Code
653
Status Date
Wednesday, April 10, 2024
Serial Number
97229628
Mark Type
4000
Filing Date
Thursday, January 20, 2022

Trademark Owner History

Classifications
41 Education services, namely providing computer training for brain and neural activity, providing information regarding psychiatric therapies and pharmacology in the field of psychedelic-based mental health treatments for humans
40 Custom manufacture for others of psychedelic-based pharmaceuticals, pharmaceutical drugs, therapeutic pharmaceuticals, and health care products namely, central nervous system health care products used to improve, treat, and prevent mental health diseases, disorders, conditions, and ailments in humans; Custom manufacture for others of psychedelic-based pharmaceuticals, drugs, therapeutic pharmaceuticals, and health care products used to treat mental conditions, illnesses, and disorders in humans
9 Downloadable computer applications for monitoring, sensing, stimulating, measuring, and training brain and neural activity during use of psychedelic-based pharmaceuticals, pharmaceutical preparations and products in humans; downloadable computer applications for use in therapy of cognitive states during use of psychedelic-based pharmaceuticals, pharmaceutical preparations and products in humans; downloadable computer software applications for monitoring, sensing, stimulating, measuring, and training brain and neural activity during use of psychedelic-based pharmaceuticals, pharmaceutical preparations and products in humans; downloadable computer software applications for use in therapy of cognitive states during use of psychedelic-based pharmaceuticals, pharmaceutical preparations and products in humans; medical systems comprising software and/or hardware for monitoring, sensing, stimulating, measuring, and training brain and neural activity during use of psychedelic-based pharmaceuticals, pharmaceutical preparations and products in humans; medical systems comprising software and/or hardware for use in therapy of cognitive states during use of psychedelic-based pharmaceuticals, pharmaceutical preparations and products in humans; downloadable software as a Medical Device (SaMD) for monitoring, sensing, stimulating, measuring, and training brain and neural activity during use of psychedelic-based pharmaceuticals, pharmaceutical preparations and products in humans; downloadable software as a Medical Device (SaMD) for use in therapy of cognitive states during use of psychedelic-based pharmaceuticals, pharmaceutical preparations and products in humans; downloadable software as a Medical Device (SaMD) for stimulating nerves during use of psychedelic-based pharmaceuticals, pharmaceutical preparations and products in humans
39 Warehousing services, namely, distribution of psychedelic-based pharmaceuticals, pharmaceutical drugs, therapeutic pharmaceuticals, and health care products, namely, central nervous system health care products used to improve, treat, and prevent diseases, disorders, conditions, and ailments in humans; Distribution services, namely, delivery of psychedelic-based pharmaceuticals, pharmaceutical drugs, therapeutic pharmaceuticals, and health care products, namely, central nervous pharmaceuticals, pharmaceutical drugs, therapeutic pharmaceuticals, and health care products, namely, central nervous system health care products used to improve, treat, and prevent diseases, disorders, conditions, and ailments in humans
5 Psychedelic-based pharmaceuticals, pharmaceutical preparations and products for the treatment of central nervous system conditions, illnesses, and disorders in humans; psychedelic-based medicines for the treatment of central nervous system conditions, illnesses, and disorders; neurogenerative psychedelic-based pharmaceutical drugs for use in humans; serotonin receptor agonists and antagonist pharmaceutical drugs for use in humans; abuse deterrent products, namely, very low-dose, low dose, and extended release psychedelic-based pharmaceutical preparations to avoid overdosing or diversion of psychedelic drugs; psychedelic-based pharmaceutical preparations for managing a mental, a behavioral, or a neuropsychiatric condition, or its symptoms, namely, motivation, attention, accuracy, response speed, perseverance, cognitive engagement, executive function, mood, behavior; therapeutics for the treatment of mental conditions, illnesses, and disorders in humans
35 Wholesale distributorship featuring psychedelic-based pharmaceuticals, drugs, therapeutic pharmaceuticals, and health care products used to improve, treat, and prevent diseases, disorders, conditions, and ailments in humans; developing marketing strategies for others in the field of psychedelic-based pharmaceuticals, drugs, and health care products used to improve, treat and prevent diseases, disorders, conditions, and ailments in humans; wholesale distributorship featuring distribution and sale of psychedelic-based pharmaceuticals, drugs, therapeutic pharmaceuticals, and health care products used to treat mental conditions, illnesses, and disorders in humans; developing marketing strategies for others in the field of psychedelic-based pharmaceuticals, drugs, therapeutic pharmaceuticals, and health care products used to treat mental conditions, illnesses, and disorders in humans
45 Licensing of proprietary information in the field of psychedelic-based pharmaceuticals, drugs, therapies, and health care products used to improve, treat, and prevent mental health diseases, disorders, conditions, illnesses, and ailments
10 Electroencephalogram (EEG) devices namely electroencephalography (EEG) device comprising a sensor for monitoring and measuring brain and neural activity for medical diagnostic purposes during use of psychedelic-based pharmaceuticals, pharmaceutical preparations and products in humans; medical devices for monitoring, sensing, measuring, and training brain and neural activity; medical devices in the nature of elecroencephalogram (EEG), electrocardiogram (EKG), magnetoencephalogram (MEG), functional near-infrared spectroscopy (fNRIS), positron emission tomography (PET), transcranial functional ultrasound, imaging devices, pupillometers, voltmeters, photodiodes, complementary metal-oxide semiconductor (CMOS), ultrasound, piezoelectric resonant devices, lead zirconate titanate (PZT), capacitive micromachined ultrasonic transducer (CMUT), micromembrane ultrasound transducer (PMUT), auditory stimulating devices, visual stimulating devices, sleep monitoring devices, thermometers, heart monitors, blood pressure monitors for use in therapy of cognitive states to monitor, sense, or measure cognitive impairment during use of psychedelic-based pharmaceuticals, pharmaceutical preparations and products in humans; medical devices for stimulating nerves during use of psychedelic-based pharmaceuticals, pharmaceutical preparations and products in humans; medical device used for treating of mental health disorders noninvasively, namely, nodes, headsets, eyewear, probes, computers, tablets, hand-held, mobile and smart phones, smart watches, wrist monitors, body monitors, including implants, body bands, rings and sleeves, fitness trackers for monitoring, sensing, stimulating, measuring, and training brain and neural activity during use of psychedelic-based pharmaceuticals, pharmaceutical preparations and products in humans; tamper resistant dosage dispensers for administering psychedelic-based medicine to human patients
42 Psychedelic-based pharmaceutical research and development for humans; psychedelic-based pharmaceutical drug development for humans; psychedelic-based pharmaceutical research and development in the field of mental health treatments for humans; psychedelic-based drug discovery services for humans; consultancy pertaining to pharmacology in the field of psychedelic-based mental health treatments in humans; psychedelic-based medical research in the field of human mental health conditions, illnesses, and disorders; neuropsychiatric drug discovery services including pre-clinical and clinical pharmaceutical psychedelic-based drug development for humans; psychedelic-based pharmaceutical drug development and discovery including new chemical entities, neurogenerative drugs, serotonin receptor agonists and antagonist, abuse deterrent drugs, and pharmaceutical preparations for managing a mental, a behavioral, or a neuropsychiatric condition, or its symptoms in humans
"THERAPEUTICS"

Trademark Events
Apr 10, 2024
Notification Of Letter Of Suspension E-Mailed
Apr 10, 2024
Letter Of Suspension E-Mailed
Apr 10, 2024
Suspension Letter Written
Mar 1, 2024
Teas/Email Correspondence Entered
Mar 1, 2024
Correspondence Received In Law Office
Mar 1, 2024
Teas Response To Office Action Received
Jan 16, 2024
Application Extension Granted/Receipt Provided
Jan 16, 2024
Application Extension To Response Period - Received
Oct 16, 2023
Notification Of Non-Final Action E-Mailed
Oct 16, 2023
Non-Final Action E-Mailed
Oct 16, 2023
Non-Final Action Written
Sep 22, 2023
Teas/Email Correspondence Entered
Sep 21, 2023
Correspondence Received In Law Office
Sep 21, 2023
Teas Response To Suspension Inquiry Received
Jun 8, 2023
Notification Of Letter Of Suspension E-Mailed
Jun 8, 2023
Letter Of Suspension E-Mailed
Jun 8, 2023
Suspension Letter Written
May 13, 2023
Teas/Email Correspondence Entered
May 12, 2023
Correspondence Received In Law Office
May 12, 2023
Teas Response To Office Action Received
Nov 12, 2022
Notification Of Non-Final Action E-Mailed
Nov 12, 2022
Non-Final Action E-Mailed
Nov 12, 2022
Non-Final Action Written
Oct 29, 2022
Assigned To Examiner
Jan 25, 2022
New Application Office Supplied Data Entered
Jan 24, 2022
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24